دورية أكاديمية
أعرض في EDS

First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq

التفاصيل البيبلوغرافية
العنوان: First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq
المؤلفون: Assan, Florence, Tubach, Florence, Arlegui, Hugo, Viguier, Manuelle, Beylot-Barry, Marie, Dupuy, Alain, Beneton, Nathalie, Joly, Pascal, Jullien, Denis, Mahe, Emmanuel, Paul, Carle F, Richard, Marie-Aleth, Bachelez, Herve, Giboin, Caroline, Chosidow, Olivier, Sbidian, Emilie
المساهمون: Hôpital Henri Mondor, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Robert Debré, Bordeaux Research In Translational Oncology Bordeaux (BaRITOn), Université de Bordeaux (UB)-CHU Bordeaux-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP), École des Hautes Études en Santé Publique EHESP (EHESP), Centre Hospitalier Le Mans (CH Le Mans), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Edouard Herriot CHU - HCL, Hospices Civils de Lyon (HCL), Centre Hospitalier Victor Dupouy, Centre d'investigation clinique de Toulouse (CIC 1436), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Marseille, Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hopital Saint-Louis AP-HP (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), French Ministry of Health PHRC AOM 09 195, French National Agency for the Safety of Medicines and Health Products (ANSM), Abbvie, MSD France, Janssen Johnson and Johnson USA Janssen Biotech Inc, Pfizer Pfizer, Departement a la Recherche Clinique et au Developpement (DRCD - Department for Clinical Research and Development), Assistance Publique - Hopitaux de Paris (Paris Hospitals), French Society of Dermatology, Psoriasis Research Group
المصدر: ISSN: 1018-8665.
بيانات النشر: HAL CCSD
Karger
سنة النشر: 2021
المجموعة: Université Toulouse III - Paul Sabatier: HAL-UPS
مصطلحات موضوعية: Psoriasis, Obesity, Biologic therapy, Drug survival, Psobioteq, [SDV]Life Sciences [q-bio]
الوصف: International audience ; Background - Obesity is associated with an increased risk of psoriasis. Objective - In this study, we examined whether body mass index (BMI) is taken into account when choosing first-line biologic therapy for psoriasis. Methods - In this cohort study, we compared obese (BMI ≥30 kg/m2) and non-obese patients for the first-line biologic therapy prescribed, its survival, reasons for discontinuation, therapy optimization, co-prescription of methotrexate and factors associated with long drug survival. Results - A total of 931 patients were included: 594 (64%) were male, median age was 46 years (interquartile range 36-56). The most-prescribed biologic agents as first-line treatment were adalimumab (ADA; 42.7%), ustekinumab (UST; 29.9%) and etanercept (ETA; 22.9%); only frequency of infliximab (IFX) prescription differed between groups. Drug survival was significantly shorter for obese than non-obese patients (p < 2.10-4) and was worse for obese than non-obese patients for UST (p = 0.009) and ETA (p = 0.02), with no difference for ADA (p = 0.11). The main reason for discontinuation was primary inefficacy (62%), which was more frequent in obese than non-obese patients. The cumulative incidence of optimization did not significantly differ between the groups, except for ADA (SHR 1.91, 95% CI [1.23-2.96], p = 0.005). On multivariate analysis, risk of discontinuation was associated with only ETA as first-line biologic therapy (HR 1.51, 95% CI 1.04-2.19). Conclusion - This study highlighted the lack of difference in prescription of first-line biologic treatment, except for IFX, between obese and non-obese patients presenting moderate-to-severe psoriasis. Drug survival in obese patients is shorter, mainly because of inefficacy, than in non-obese patients. This highlights the need for targeted pharmacological studies in obese individuals to find optimal administration schemes.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33535213; hal-03156232; https://hal.science/hal-03156232Test; PUBMED: 33535213
DOI: 10.1159/000513398
الإتاحة: https://doi.org/10.1159/000513398Test
https://hal.science/hal-03156232Test
رقم الانضمام: edsbas.E8B69214
قاعدة البيانات: BASE
ResultId 1
Header edsbas
BASE
edsbas.E8B69214
857
3
Academic Journal
academicJournal
856.820373535156
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.E8B69214&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://doi.org/10.1159/000513398# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Assan%2C+Florence%22&quot;&gt;Assan, Florence&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Tubach%2C+Florence%22&quot;&gt;Tubach, Florence&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Arlegui%2C+Hugo%22&quot;&gt;Arlegui, Hugo&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Viguier%2C+Manuelle%22&quot;&gt;Viguier, Manuelle&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Beylot-Barry%2C+Marie%22&quot;&gt;Beylot-Barry, Marie&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Dupuy%2C+Alain%22&quot;&gt;Dupuy, Alain&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Beneton%2C+Nathalie%22&quot;&gt;Beneton, Nathalie&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Joly%2C+Pascal%22&quot;&gt;Joly, Pascal&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Jullien%2C+Denis%22&quot;&gt;Jullien, Denis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mahe%2C+Emmanuel%22&quot;&gt;Mahe, Emmanuel&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Paul%2C+Carle+F%22&quot;&gt;Paul, Carle F&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Richard%2C+Marie-Aleth%22&quot;&gt;Richard, Marie-Aleth&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bachelez%2C+Herve%22&quot;&gt;Bachelez, Herve&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Giboin%2C+Caroline%22&quot;&gt;Giboin, Caroline&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Chosidow%2C+Olivier%22&quot;&gt;Chosidow, Olivier&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sbidian%2C+Emilie%22&quot;&gt;Sbidian, Emilie&lt;/searchLink&gt; )
Array ( [Name] => Author [Label] => Contributors [Group] => Au [Data] => H&#244;pital Henri Mondor&lt;br /&gt;Institut Pierre Louis d&#39;Epid&#233;miologie et de Sant&#233; Publique (iPLESP)&lt;br /&gt;Institut National de la Sant&#233; et de la Recherche M&#233;dicale (INSERM)-Sorbonne Université (SU)&lt;br /&gt;CHU Piti&#233;-Salp&#234;tri&#232;re AP-HP&lt;br /&gt;Assistance publique - H&#244;pitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)&lt;br /&gt;H&#244;pital Robert Debr&#233;&lt;br /&gt;Bordeaux Research In Translational Oncology Bordeaux (BaRITOn)&lt;br /&gt;Universit&#233; de Bordeaux (UB)-CHU Bordeaux-Institut National de la Sant&#233; et de la Recherche M&#233;dicale (INSERM)&lt;br /&gt;Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou&lt;br /&gt;Recherche en Pharmaco-&#233;pid&#233;miologie et Recours aux Soins (REPERES)&lt;br /&gt;Universit&#233; de Rennes (UR)-&#201;cole des Hautes &#201;tudes en Sant&#233; Publique EHESP (EHESP)&lt;br /&gt;&#201;cole des Hautes &#201;tudes en Sant&#233; Publique EHESP (EHESP)&lt;br /&gt;Centre Hospitalier Le Mans (CH Le Mans)&lt;br /&gt;Physiopathologie, Autoimmunit&#233;, maladies Neuromusculaires et THErapies R&#233;g&#233;n&#233;ratrices (PANTHER)&lt;br /&gt;Universit&#233; de Rouen Normandie (UNIROUEN)&lt;br /&gt;Normandie Universit&#233; (NU)-Normandie Universit&#233; (NU)-Institut National de la Sant&#233; et de la Recherche M&#233;dicale (INSERM)&lt;br /&gt;H&#244;pital Edouard Herriot CHU - HCL&lt;br /&gt;Hospices Civils de Lyon (HCL)&lt;br /&gt;Centre Hospitalier Victor Dupouy&lt;br /&gt;Centre d&#39;investigation clinique de Toulouse (CIC 1436)&lt;br /&gt;Universit&#233; Toulouse III - Paul Sabatier (UT3)&lt;br /&gt;Universit&#233; de Toulouse (UT)-Universit&#233; de Toulouse (UT)-Institut National de la Sant&#233; et de la Recherche M&#233;dicale (INSERM)-P&#244;le Sant&#233; publique et m&#233;decine publique CHU Toulouse&lt;br /&gt;Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)&lt;br /&gt;CHU Marseille&lt;br /&gt;Imagine - Institut des maladies g&#233;n&#233;tiques (IHU) (Imagine - U1163)&lt;br /&gt;Institut National de la Sant&#233; et de la Recherche M&#233;dicale (INSERM)-Universit&#233; Paris Cit&#233; (UPCit&#233;)&lt;br /&gt;Hopital Saint-Louis AP-HP (AP-HP)&lt;br /&gt;Assistance publique - H&#244;pitaux de Paris (AP-HP) (AP-HP)&lt;br /&gt;Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE)&lt;br /&gt;Universit&#233; Paris-Est Cr&#233;teil Val-de-Marne - Paris 12 (UPEC UP12)&lt;br /&gt;French Ministry of Health PHRC AOM 09 195&lt;br /&gt;French National Agency for the Safety of Medicines and Health Products (ANSM)&lt;br /&gt;Abbvie&lt;br /&gt;MSD France&lt;br /&gt;Janssen Johnson and Johnson USA Janssen Biotech Inc&lt;br /&gt;Pfizer Pfizer&lt;br /&gt;Departement a la Recherche Clinique et au Developpement (DRCD - Department for Clinical Research and Development), Assistance Publique - Hopitaux de Paris (Paris Hospitals)&lt;br /&gt;French Society of Dermatology&lt;br /&gt;Psoriasis Research Group )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => &lt;i&gt;ISSN: 1018-8665&lt;/i&gt;. )
Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => HAL CCSD&lt;br /&gt;Karger )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2021 )
Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Universit&#233; Toulouse III - Paul Sabatier: HAL-UPS )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Psoriasis%22&quot;&gt;Psoriasis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Obesity%22&quot;&gt;Obesity&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Biologic+therapy%22&quot;&gt;Biologic therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Drug+survival%22&quot;&gt;Drug survival&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Psobioteq%22&quot;&gt;Psobioteq&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22[SDV]Life+Sciences+[q-bio]%22&quot;&gt;[SDV]Life Sciences [q-bio]&lt;/searchLink&gt; )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => International audience ; Background - Obesity is associated with an increased risk of psoriasis. Objective - In this study, we examined whether body mass index (BMI) is taken into account when choosing first-line biologic therapy for psoriasis. Methods - In this cohort study, we compared obese (BMI ≥30 kg/m2) and non-obese patients for the first-line biologic therapy prescribed, its survival, reasons for discontinuation, therapy optimization, co-prescription of methotrexate and factors associated with long drug survival. Results - A total of 931 patients were included: 594 (64%) were male, median age was 46 years (interquartile range 36-56). The most-prescribed biologic agents as first-line treatment were adalimumab (ADA; 42.7%), ustekinumab (UST; 29.9%) and etanercept (ETA; 22.9%); only frequency of infliximab (IFX) prescription differed between groups. Drug survival was significantly shorter for obese than non-obese patients (p &lt; 2.10-4) and was worse for obese than non-obese patients for UST (p = 0.009) and ETA (p = 0.02), with no difference for ADA (p = 0.11). The main reason for discontinuation was primary inefficacy (62%), which was more frequent in obese than non-obese patients. The cumulative incidence of optimization did not significantly differ between the groups, except for ADA (SHR 1.91, 95% CI [1.23-2.96], p = 0.005). On multivariate analysis, risk of discontinuation was associated with only ETA as first-line biologic therapy (HR 1.51, 95% CI 1.04-2.19). Conclusion - This study highlighted the lack of difference in prescription of first-line biologic treatment, except for IFX, between obese and non-obese patients presenting moderate-to-severe psoriasis. Drug survival in obese patients is shorter, mainly because of inefficacy, than in non-obese patients. This highlights the need for targeted pharmacological studies in obese individuals to find optimal administration schemes. )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => info:eu-repo/semantics/altIdentifier/pmid/33535213; hal-03156232; https://hal.science/hal-03156232; PUBMED: 33535213 )
Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1159/000513398 )
Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.1159/000513398&lt;br /&gt;https://hal.science/hal-03156232 )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.E8B69214 )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1159/000513398 ) ) [Languages] => Array ( [0] => Array ( [Text] => English ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => Psoriasis [Type] => general ) [1] => Array ( [SubjectFull] => Obesity [Type] => general ) [2] => Array ( [SubjectFull] => Biologic therapy [Type] => general ) [3] => Array ( [SubjectFull] => Drug survival [Type] => general ) [4] => Array ( [SubjectFull] => Psobioteq [Type] => general ) [5] => Array ( [SubjectFull] => [SDV]Life Sciences [q-bio] [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Assan, Florence ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Tubach, Florence ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Arlegui, Hugo ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Viguier, Manuelle ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Beylot-Barry, Marie ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Dupuy, Alain ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Beneton, Nathalie ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Joly, Pascal ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jullien, Denis ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Mahe, Emmanuel ) ) ) [10] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Paul, Carle F ) ) ) [11] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Richard, Marie-Aleth ) ) ) [12] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Bachelez, Herve ) ) ) [13] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Giboin, Caroline ) ) ) [14] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Chosidow, Olivier ) ) ) [15] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Sbidian, Emilie ) ) ) [16] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hôpital Henri Mondor ) ) ) [17] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP) ) ) ) [18] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU) ) ) ) [19] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => CHU Pitié-Salpêtrière AP-HP ) ) ) [20] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU) ) ) ) [21] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hôpital Robert Debré ) ) ) [22] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Bordeaux Research In Translational Oncology Bordeaux (BaRITOn) ) ) ) [23] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Université de Bordeaux (UB)-CHU Bordeaux-Institut National de la Santé et de la Recherche Médicale (INSERM) ) ) ) [24] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou ) ) ) [25] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES) ) ) ) [26] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP) ) ) ) [27] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => École des Hautes Études en Santé Publique EHESP (EHESP) ) ) ) [28] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Centre Hospitalier Le Mans (CH Le Mans) ) ) ) [29] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER) ) ) ) [30] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Université de Rouen Normandie (UNIROUEN) ) ) ) [31] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM) ) ) ) [32] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hôpital Edouard Herriot CHU - HCL ) ) ) [33] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hospices Civils de Lyon (HCL) ) ) ) [34] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Centre Hospitalier Victor Dupouy ) ) ) [35] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Centre d'investigation clinique de Toulouse (CIC 1436) ) ) ) [36] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Université Toulouse III - Paul Sabatier (UT3) ) ) ) [37] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique CHU Toulouse ) ) ) [38] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse) ) ) ) [39] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => CHU Marseille ) ) ) [40] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163) ) ) ) [41] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité) ) ) ) [42] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hopital Saint-Louis AP-HP (AP-HP) ) ) ) [43] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP) ) ) ) [44] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE) ) ) ) [45] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12) ) ) ) [46] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => French Ministry of Health PHRC AOM 09 195 ) ) ) [47] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => French National Agency for the Safety of Medicines and Health Products (ANSM) ) ) ) [48] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Abbvie ) ) ) [49] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => MSD France ) ) ) [50] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Janssen Johnson and Johnson USA Janssen Biotech Inc ) ) ) [51] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Pfizer Pfizer ) ) ) [52] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Departement a la Recherche Clinique et au Developpement (DRCD - Department for Clinical Research and Development), Assistance Publique - Hopitaux de Paris (Paris Hospitals) ) ) ) [53] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => French Society of Dermatology ) ) ) [54] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Psoriasis Research Group ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 01 [Type] => published [Y] => 2021 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-locals [Value] => edsbas ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => ISSN: 1018-8665 [Type] => main ) ) ) ) ) ) )
IllustrationInfo